Finance

Lists
Q3 2026 earnings • in 2 days
See details
IRWD:NASDAQ
Ironwood Pharmaceuticals, Inc.
$3.46
-1.14%
(-0.040) 1D
$3.49
+0.87% (+0.030)
After hours
Closed: Nov 2, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IRWD...
Open
$3.50
High
$3.58
Low
$3.43
Mkt. cap
571.73M
Avg. vol.
1.81M
Volume
42.00
P/E ratio
4.56
52-wk high
$5.78
52-wk low
$1.76
EPS
$0.76
Beta
0.22
Shares outstanding
165.24M
No. of employees
100
Open
$3.50
High
$3.58
Low
$3.43
Mkt. cap
571.73M
Avg. vol.
1.81M
Volume
42.00
P/E ratio
4.56
52-wk high
$5.78
52-wk low
$1.76
EPS
$0.76
Beta
0.22
Shares outstanding
165.24M
No. of employees
100
News stories
From web sources and news partners
Profile
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler's diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. Wikipedia
About Ironwood Pharmaceuticals, Inc.
CEO-
Employees100
Founded1998
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websiteironwoodpharma.com
Analyst
Recommendation
Action
Price target
Projected
Date
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
-
-
07/14/2026
Mohit Bansal
Wells Fargo
Hold
Maintained
$5.00
+44.5%
05/05/2026
Jason Butler
Citizens JMP
Buy
Maintained
$10.00
+189%
02/26/2026
Next call in 2 days
Thu, Nov 5, 8:30 AM
Fiscal period
Q3 2026
- / $0.31
Revenue / Est. (USD)
- / 121.57M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
122.06M
47.71M
106.51M
113.04M
Cost of goods sold
22.47M
21.86M
21.94M
22.42M
Cost of revenue
22.47M
21.86M
21.94M
22.42M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
21.91M
19.10M
12.03M
11.31M
Operating expense
21.91M
19.10M
12.03M
11.31M
Total operating expenses
44.38M
40.96M
33.97M
33.73M
Operating income
77.68M
6.75M
72.53M
79.31M
Other non operating income
40.00K
-116.00K
42.00K
42.00K
EBT including unusual items
68.02M
455.00K
65.17M
73.73M
EBT excluding unusual items
70.22M
203.00K
65.13M
73.73M
Income tax expense
27.94M
2.73M
24.40M
22.44M
Effective tax rate
41.08%
600.22%
37.44%
30.43%
Other operating expenses
-
-
-
-
Net income
40.08M
-2.28M
40.77M
51.29M
Net profit margin
32.84%
-4.77%
38.28%
45.37%
Earnings per share
0.24
-0.01
0.24
0.31
Interest and investment income
930.00K
1.46M
1.70M
1.58M
Interest expense
-8.43M
-7.89M
-9.14M
-7.20M
Net interest expenses
-7.50M
-6.43M
-7.44M
-5.62M
Depreciation and amortization charges
-
-
-
-
EBITDA
78.16M
7.21M
72.98M
79.76M
Gain or loss from assets sale
7.00K
-3.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps